Oncology Clinical Trials Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Oncology Clinical Trials Market Report is Segmented by Phase (Phase I, Phase II, Phase III, and Phase IV), Design (Treatment Studies and Observational Studies), Cancer Type (Lung Cancer, Breast Cancer, Leukemia, Prostate Cancer, and Other Cancer Types), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers the Market Sizes and Forecasts in Value (USD) for the Above Segments.

Oncology Clinical Trials Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Oncology Clinical Trials Market Size

Global Oncology Clinical Trials Market (2024 - 2029)
Study Period 2019 - 2030
Base Year For Estimation 2024
Forecast Data Period 2025 - 2030
CAGR 15.00 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Medium

Major Players

Oncology Clinical Trials Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Global Oncology Clinical Trials Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Oncology Clinical Trials Market Analysis

The Global Oncology Clinical Trials Market is expected to register a CAGR of 15% during the forecast period.

The increasing number of cancer cases, the rising need for precision medicines, and high research and development (R&D) spending by the pharmaceutical industry in oncology are key factors driving the market's growth. For instance, according to Cancer Facts and Figures 2024, published in January 2024 by the American Cancer Society, an estimated 2.00 million new cancer cases were diagnosed in 2024, up from 1.93 million in 2023, among which prostate cancer cases were estimated to be 288,300, followed by 238,340 cases of lung cancer and 300,590 cases of female breast cancer. The increased prevalence of cancer and growing demand for effective treatment are likely to lead to a rise in drug development activities, thereby boosting market growth over the forecast period.

The increasing research and development spending on cancer is expected to boost the market over the forecast period. For instance, in August 2022, Griffith University took a significant step forward in cancer research by launching two new research centers with a USD 4.6 million grant from the Australian Cancer Research Foundation (ACRF). Such research initiatives and funding for cancer research programs create opportunities for market players to invest in research and bring advanced oncology drug molecules into the market, which is anticipated to boost market growth over the forecast period.

Moreover, an increase in pipeline drugs from key market players for the treatment of various cancers and the launch of clinical trials are expected to contribute to market growth over the forecast period. For instance, in January 2024, the Royal Surrey NHS Foundation Trust in the United Kingdom reported the commencement of a clinical trial analyzing a vaccine aimed at treating early-stage bowel cancer in patients from both the United Kingdom and Australia.

Similarly, in April 2024, BioNTech SE released three-year follow-up data from a Phase 1 trial on its mRNA-based personalized neoantigen-specific immunotherapy, known as iNeST, under the name autogenous cerumen (BNT122, RO7198457). This trial focused on patients who had undergone surgery for pancreatic ductal adenocarcinoma (PDAC). The results revealed that autogenous cevumeran triggered an immune response in 8 out of 16 patients, lasting up to three years, as evidenced by activated T cells. Notably, patients with sustained T cell presence also showed a prolonged median recurrence-free survival, highlighting the potential of this cancer vaccine. Such ongoing clinical research activities are expected to contribute to market growth over the forecast period.

The oncology clinical trials market is poised for growth, driven by rising cancer cases and increased research and development in oncology. However, strict regulations surrounding patient enrollment in clinical trials act as a constraint on market expansion.

Oncology Clinical Trials Industry Overview

The oncology clinical trials market is fragmented. Major pharmaceutical companies have been found to make enormous investments in R&D, especially in emerging nations, to gain opportunities for market growth in major regions. The strategic partnerships between pharmaceutical companies and CROs are expected to have a significant impact on the market's growth. Some major market players include Novartis AG, Merck & Co. Inc., Bristol Myers Squibb Company, F Hoffmann-La Roche Ltd, and Pfizer Inc.

Oncology Clinical Trials Market Leaders

  1. Novartis AG

  2. Merck & Co Inc.

  3. F Hoffmann-La Roche Ltd

  4. Pfizer Inc.

  5. Bristol Myers Squibb Company

  6. *Disclaimer: Major Players sorted in no particular order
Oncology Clinical Trials Market Concentration
Need More Details on Market Players and Competiters?
Download PDF

Oncology Clinical Trials Market News

  • January 2024: Ipsen presented for Cabometyx (cabozantinib) in combination with immunotherapy across indications at the American Society of Clinical Oncology Genitourinary Symposium (ASCO GU) that took place from January 25-27, 2024, in San Francisco, United States.
  • January 2024: Transgene and NEC Corporation announced the signing of a further development collaboration agreement to continue the clinical evaluation of the individualized neoantigen cancer vaccine, TG4050.

Global Oncology Clinical Trials Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Cancer Worldwide
    • 4.2.2 Increasing Role of Precision and Personalized Medicine for Cancer Treatment
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulations for Patient Enrollment
  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.4.1 Bargaining Power of Buyers/Consumers
    • 4.4.2 Bargaining Power of Suppliers
    • 4.4.3 Threat of New Entrants
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Phase
    • 5.1.1 Phase I
    • 5.1.2 Phase II
    • 5.1.3 Phase III
    • 5.1.4 Phase IV
  • 5.2 By Design
    • 5.2.1 Treatment Studies
    • 5.2.2 Observational Studies
  • 5.3 By Cancer Type
    • 5.3.1 Lung Cancer
    • 5.3.2 Breast Cancer
    • 5.3.3 Leukemia
    • 5.3.4 Prostate Cancer
    • 5.3.5 Other Cancer Types
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Johnson & Johnson
    • 6.1.2 Pfizer Inc
    • 6.1.3 F Hoffmann-La Roche Ltd
    • 6.1.4 Novartis AG
    • 6.1.5 Merck & Co. Inc.
    • 6.1.6 GlaxoSmithKline PLC
    • 6.1.7 Sanofi
    • 6.1.8 AbbVie Inc.
    • 6.1.9 AstraZeneca PLC
    • 6.1.10 Bristol Myers Squibb Company
    • 6.1.11 Eli Lilly and Company
    • 6.1.12 Astellas Pharma Inc.
    • 6.1.13 Boehringer Ingelheim GmbH
    • 6.1.14 Takeda Pharmaceutical Company Limited
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers- Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Oncology Clinical Trials Industry Segmentation

As per the scope of the report, oncology clinical trials are experiments that are conducted under clinical research and follow a regulated protocol. These experiments are primarily performed to obtain data regarding the safety and efficacy of newly developed drugs. Clinical trial data is mandatory for drug approval and for it to be introduced in the market. These trials are performed under different phases, which depend upon various factors.

The oncology clinical trials market is segmented by phase, design, cancer type, and geography. By phase, the market is segmented into Phase I, Phase II, Phase III, and Phase IV. By design, the market is segmented into treatment studies and observational studies. By cancer type, the market is segmented into lung cancer, breast cancer, leukemia, prostate cancer, and other cancer types. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the market forecasts and sizes in value (USD) for the above segments.

By Phase Phase I
Phase II
Phase III
Phase IV
By Design Treatment Studies
Observational Studies
By Cancer Type Lung Cancer
Breast Cancer
Leukemia
Prostate Cancer
Other Cancer Types
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Global Oncology Clinical Trials Market Research Faqs

What is the current Global Oncology Clinical Trials Market size?

The Global Oncology Clinical Trials Market is projected to register a CAGR of 15% during the forecast period (2025-2030)

Who are the key players in Global Oncology Clinical Trials Market?

Novartis AG, Merck & Co Inc., F Hoffmann-La Roche Ltd, Pfizer Inc. and Bristol Myers Squibb Company are the major companies operating in the Global Oncology Clinical Trials Market.

Which is the fastest growing region in Global Oncology Clinical Trials Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Global Oncology Clinical Trials Market?

In 2025, the North America accounts for the largest market share in Global Oncology Clinical Trials Market.

What years does this Global Oncology Clinical Trials Market cover?

The report covers the Global Oncology Clinical Trials Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Global Oncology Clinical Trials Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Global Oncology Clinical Trials Industry Report

The global oncology market is segmented by phase, design, cancer type, and geography, providing a comprehensive industry overview. The market forecast includes detailed industry analysis and market segmentation, highlighting the market leaders in various regions such as North America, Europe, Asia-Pacific, the Middle-East and Africa, and South America. The report example includes valuable market data, industry trends, and market predictions, offering a thorough market review and industry outlook.

The industry research covers the growth rate and market growth, providing insights into the industry size and market value. The market report also includes a report PDF, which contains industry information and industry statistics. The market analysis focuses on market segmentation and market trends, offering a detailed market overview and market forecast.

The report highlights the importance of market research and the role of research companies in providing accurate market data. The industry reports include a market outlook and market review, offering a comprehensive view of the market segmentation and market value. The industry sales and market predictions are also covered, providing a detailed market overview and market growth.

In summary, the global oncology market report provides a thorough industry analysis, covering all aspects of the market, including growth rate, industry size, industry trends, and market segmentation. The report is an essential resource for understanding the market value and market outlook, offering valuable insights into the market leaders and market predictions. The report PDF is available for download, providing a comprehensive view of the market data and industry information.